Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Amyloidosis; Systemic Clinical Trial

— AT02-001  

Official title:

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05521022
• Other study ID #: AT02-001
• Status: Recruiting
• Phase: Phase 1
• Start date: September 1, 2022
• Est. completion date: March 1, 2025

Study information

• Verified date: April 2024
• Source: Attralus, Inc.
• Contact: Scott Stephens, RN
• Phone: 3212287400
• Email: Sstephens[@]attralus.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.

Description:

Systemic amyloidosis is an incurable disease, and about 20% of patients with cardiac or advanced kidney involvement experience early deaths (<1 year). Despite recent progress in proteasome inhibitors, chemotherapies, and immunotherapies that target plasma cells have greatly improved the prognosis of patients with systemic amyloidosis, median survival remains low at approximately five years.

AT-02 (INN: not yet available) is a full-length, humanized, recombinant immunoglobulin 1 (IgG1)-like glycoprotein monoclonal antibody (mAb) that is being developed to treat systemic amyloidosis.

This is a three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers (HV) and in subjects with systemic amyloidosis (SA) and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.

Part 1 is a double-blind, single-center, single-ascending dose escalation study in HV to assess the safety, tolerability, and PK of AT-02. Healthy volunteers between 18 to 56 years of will be enrolled in the Part 1 study.

Part 2 is an open-label, single-ascending dose escalation study in subjects with systemic amyloidosis to assess the safety, tolerability, and PK of AT-02 and to identify a maximum tolerated dose (MTD). Subjects with SA over 18 years of age will be involved in the Part 2 study.

Part 3 is an open-label, multiple-ascending dose, dose escalation study in subjects with systemic amyloidosis to assess the safety, tolerability, PK, PD, and clinical activity of multiple doses of AT-02. Subjects with SA ≥18 and ≤85 years of age will be involved in the Part 3 study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 1, 2025
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Eligibility Criteria for Healthy Volunteers:

Healthy volunteers are eligible to be included in the study only if all the following criteria apply:

1. Understands the study procedures and can give signed informed consent

2. Male or female between >18 and <56 years of age.

3. Willing and able to comply with this protocol and informed consent and be available for the entire duration of the study.

4. Willing to abstain from alcohol and strenuous physical activity (i.e., strenuous or unaccustomed weightlifting, running, bicycling, etc.) from 48 hours prior to study treatment administration until discharge from the clinical unit and prior to each outpatient visit.

5. In good general health, determined by no clinically significant findings in the opinion of the Investigator from medical history, physical examination, 12-lead electrocardiogram (ECG), clinical laboratory findings, and vital signs at Screening and Phase 1 unit Check-in.

6. Has body mass index (BMI) of 18 to 32 kg/m2, inclusive.

7. Women of childbearing potential (WOCBP)

1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug.

2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.

3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.

8. Postmenopausal females:

a) Postmenopausal females under the age of 55 years must have a documented serum follicle stimulating hormone (FSH) level >40 mIU/mL to confirm menopause

9. Women of non-childbearing potential (WONCBP) and female participants with vasectomized male partners:

a) WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.

10. Male participants:

1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.

2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.

3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.

4. Male participants with potentially postmenopausal partners who are under the age of 55 years must use condoms unless their partner's postmenopausal status has been confirmed by FSH level.

5. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.

Eligibility Criteria for Part 2 Subjects with Systemic Amyloidosis

Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:

1. Understands the study procedures and can give signed informed consent

2. Male or female =18 and =80 years of age.

3. Mini Mental Status Exam (MMSE) score >27 (subjects >55 years of age only).

4. Has a confirmed diagnosis of AL, ATTR, or other form of systemic amyloidosis, based on any one of the following:

1. A histologic confirmation with a biopsy containing deposits of apple-green birefringent, Congophilic material or other amyloid staining (i.e., thioflavin T or sulfated alcian blue) with confirmatory immunohistochemistry, mass spectrometry or identification of an amyloidogenic genetic variant;

2. Genetic screening with presence of amyloid-related pathology; or

3. Amyloid-specific imaging study (e.g., bone scintigraphy and echocardiogram/CMR consistent with ATTR cardiac amyloid).

5. Subjects with AL systemic amyloidosis must have achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains <40 mg/L) and within 12 months of Screening and may be receiving maintenance daratumumab.

6. Subjects with ATTR systemic amyloidosis may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.

7. Women of childbearing potential (WOCBP):

1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.

2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.

3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.

8. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:

1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.

2. Postmenopausal females must have a documented serum FSH level >40 mIU/mL at Screening to confirm menopause.

9. Male participants:

1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.

2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.

3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.

4. Male participants in same-sex relationships or in relationships with WONCBP, must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.

Eligibility Criteria for Part 3 Subjects with Systemic Amyloidosis

Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:

1. Understands the study procedures and can give signed informed consent.

2. Male or female =18 and =85 years of age.

3. Has a confirmed diagnosis of ATTR cardiomyopathy (ATTR-CM), AL, or other form of systemic amyloidosis

4. Imaging evidence of organ amyloid deposits.

5. For ATTR cardiomyopathy subjects, genetic testing confirming wild type ATTR or identification of an amyloidogenic genetic variant is required. If genetic testing has not been performed prior to screening, then the test may be ordered during screening

6. Subjects with ATTR cardiomyopathy may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.

7. Subjects with AL systemic amyloidosis may be receiving maintenance daratumumab and must have

1. Achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains <40 mg/L) within 12 months of Screening or

2. Achieved a partial hematologic response, is in stable condition (defined as >6 months without clonal or amyloidotic organ progression), is not receiving plasma cell directed (PCD) therapy and is not expected to require PCD therapy for the duration of the study.

8. Women of childbearing potential (WOCBP):

1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.

2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.

3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.

9. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:

1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.

2. Postmenopausal females must have a documented serum FSH level >40 mIU/mL at Screening to confirm menopause.

10. Male participants:

1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.

2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.

3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.

4. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.

Related Conditions & MeSH terms

• Amyloidosis
• Amyloidosis; Systemic

Intervention

Drug:
• AT-02
AT-02 via IV infusion

Other:
• AT-02 (Placebo)
Normal saline solution via IV infusion

Locations

Country	Name	City	State
Australia	Flinders Medical Centre	Bedford Park	South Australia
Australia	Box Hill Hospital	Box Hill	Victoria
Australia	Q-Pharm Pty Ltd	Herston	Queensland
Australia	Royal Perth Hospital	Perth	Western Australia
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
United States	Johns Hopkins	Baltimore	Maryland
United States	Cleveland Clinic	Cleveland	Ohio
United States	St. Luke's Hospital of Kansas City	Kansas City	Missouri
United States	Midwest Heart and Vascular	Overland Park	Kansas
United States	Penn Presbyterian Medical Center	Philadelphia	Pennsylvania
United States	OHSU (Oregon Health & Science University)	Portland	Oregon

Sponsors (2)

Lead Sponsor	Collaborator
Attralus, Inc.	Novotech (Australia) Pty Limited

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of treatment-emergent adverse events (TEAEs) from Day 1 to end of study (EOS).	Safety will be assessed by review of clinical laboratory parameters and incidence and severity of TEAEs (graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5).	Up to 57+/-7 days
Primary	Incidence of dose-limiting toxicities (DLTs) in subjects with systemic amyloidosis.	A DLT is defined as any related TEAE with a National Cancer Institute (NCI) CTCAE version 5.0 Grade =3 which also represents a shift from Baseline clinical status of >1 NCI CTCAE Grade.	Up to 85+/-7 Days
Primary	Incidence and frequency of abnormal and clinically significant abnormal clinical laboratory parameter values.		Up to 85+/-7 Days
Primary	Incidence of treatment-emergent anti-drug antibodies (ADA)	The number and percentage of subjects who develop detectable ADA will be summarized by dose cohort.	Up to 85+/-7 Days
Secondary	To determine the plasma pharmacokinetics (PK) profile of AT-02	Parameter: time to maximum observed AT-02 concentration (Tmax).	Up to 85+/-7 Days
Secondary	To determine the plasma pharmacokinetics (PK) profile of AT-02	Parameter: maximum observed concentration of AT-02 (Cmax).	Up to 85+/-7 Days
Secondary	To determine the plasma pharmacokinetics (PK) profile of AT-02	Parameter: area under the plasma concentration versus time curve (AUC).	Up to 85+/-7 Days
Secondary	To determine the plasma pharmacokinetics (PK) profile of AT-02	Parameter: volume of distribution at steady state (Vss).	Up to 85+/-7 Days
Secondary	To determine the plasma pharmacokinetics (PK) profile of AT-02	Parameter: total body clearance (CL) of AT-02.	Up to 85+/-7 Days
Secondary	To determine the plasma pharmacokinetics (PK) profile of AT-02	Parameter: AT-02 half-life (t1/2).	Up to 85+/-7 Days